| Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. | |
| | |
MedLine Citation:
|
PMID: 17699476 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: C.E.R.A., a continuous erythropoietin receptor activator, is in development to provide anemia correction and stable maintenance of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy and safety when administered up to once monthly in patients who have CKD and are on dialysis and randomly convert directly from epoetin alpha or beta one to three times weekly. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: In this three-arm, comparator-controlled, open-label, randomized, parallel-group, Phase III study, 572 dialysis patients (> or =18 yr) who were receiving stable subcutaneous epoetin one to three times weekly were randomly assigned (1:1:1) to continue epoetin or to receive subcutaneous C.E.R.A. once monthly or twice monthly for 52 wk. Dosage was adjusted to maintain Hb +/-1.0 g/dl of baseline level. Primary end point was mean change in Hb level between baseline and the evaluation period (weeks 29 to 36). RESULTS: Mean Hb levels during the evaluation period were similar between groups (once-monthly C.E.R.A. 11.5 g/dl; twice-monthly C.E.R.A. 11.7 g/dl; epoetin 11.5 g/dl). The difference between C.E.R.A. and epoetin in mean change (97.5% confidence interval) in Hb concentration between baseline and evaluation was -0.022 g/dl (-0.262 to 0.217) for once monthly and 0.141 g/dl (-0.098 to 0.380) for twice monthly. Analysis demonstrated that C.E.R.A. was as effective as epoetin in maintaining Hb and was well tolerated. CONCLUSIONS: Subcutaneous C.E.R.A. once or twice monthly successfully maintained tight and stable Hb levels in patients who were on dialysis and randomly converted directly from epoetin one to three times weekly. |
| | |
Authors:
|
Wladyslaw Sulowicz; Francesco Locatelli; Jean-Philippe Ryckelynck; Jozsef Balla; Botond Csiky; Kevin Harris; Patricia Ehrhard; Ulrich Beyer; |
Related Documents
:
|
4632136 - Rickettsial hemolysis: adsorption of rickettsiae to erythrocytes. 8569946 - Carbamylated hemoglobin in prerenal azotemia. 2251966 - Thiamine status of healthy and institutionalized elderly subjects: analysis of dietary ... 11081466 - The paradox of hematocrit in exercise physiology: which is the "normal" range from an h... 12204956 - In vitro whole-blood analysis of cellular immunity in patients with active coccidioidom... 1533266 - The effectiveness of weight-belts during multiple repetitions of the squat exercise. |
Publication Detail:
|
Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-05-23 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 2 ISSN: 1555-905X ISO Abbreviation: - Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-08-16 Completed Date: 2007-09-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 637-46 Citation Subset: IM |
Affiliation:
|
Clinic of Nephrology Collegium Medicum, Jagiellonian University, Cracow, Poland. wladsul@mp.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia
/
blood*,
drug therapy*,
etiology Chronic Disease Drug Administration Schedule Epoetin Alfa / therapeutic use* Erythropoietin / administration & dosage* Erythropoietin, Recombinant / therapeutic use* Female Hematinics / therapeutic use* Hemoglobins / analysis* Humans Injections, Subcutaneous Kidney Diseases / blood*, complications Male Middle Aged Polyethylene Glycols / administration & dosage* Renal Dialysis* |
| Chemical | |
Reg. No./Substance:
|
0/Erythropoietin, Recombinant; 0/Hematinics; 0/Hemoglobins; 0/Polyethylene Glycols; 0/continuous erythropoietin receptor activator; 0/epoetin beta; 11096-26-7/Erythropoietin; 113427-24-0/Epoetin Alfa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
Next Document: Influence of peritoneal dialysis training nurses' experience on peritonitis rates.